OVERVIEW
OUR EQUITY STORY
UCB FINANCIALS
UCB GOVERNANCE
OUR SHAREHOLDERS
ESG OVERVIEW
DOWNLOAD CENTER
NEWS
UCB STORIES
CONTACT
SETTINGS
UCB.COM
SHARE APP
Share information
285.10 €
-0.59 %
18/11/2026 17:35
Open
High
Low
Volume
287.30 €
289.00 €
285.10 €
235,516
Latest News
09-Nov-2026
BE BOLD: BIMZELX[®] (bimekizumab-bkzx) builds on superior joint responses versus SKYRIZI[®] (risankizumab) at Week 16, with clinical improvements sustained through Week 24
09-Nov-2026
BE BOLD: BIMZELX[[®]] (bimekizumab-bkzx) builds on superior joint responses versus SKYRIZI[®] (risankizumab) at Week 16, with clinical improvements sustained through Week 24
09-Nov-2026
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
04-Nov-2026
UCB advances its digital antibody engineering program with new Cradle collaboration
Interim reports
30-Jul-2026
2026 half-year results
26-Feb-2026
2025 full-year result
31-Jul-2025
2025 half-year results
UCB Stories
30-Jul-2026
Delivering today, shaping what comes next
26-Feb-2026
Strong execution in service of patients and sustainable value
31-Jul-2025
Stronger every semester - From differentiated innovation to outstanding delivery
In Focus
30-Jul-2026 2026 Half-Year Results